TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07173595: A Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies

Sponsor: Qilu Pharmaceutical Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 186 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07173595 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07173595 Rescue Dossier →